18 Jul Satellite Biosciences
Tom Lowery, President and CEO
Oct. 6 | 3:45pm | FLW Ballroom G
Water Town, MA
(Private)
Satellite Bio is a clinical-stage regenerative medicine company developing the first sustainable, scalable, off-the-shelf hepatocyte cell therapies for severe liver disease. Our GMP-compliant hepatocyte expansion technology enables 10M+ fold expansion of primary human hepatocytes while preserving adult function, solving a supply bottleneck the field has faced for decades. Our manufacturing is more like a traditional drug than a cell therapy: centrally produced, cryopreserved, and shipped off-the-shelf at a cost of goods under $10,000 per dose. Our lead program, SB-101, is a first-in-human Phase 1/2 trial delivering functional metabolic rescue for infants with severe, early-onset urea cycle disorders (UCD), a population with 25–50% mortality under current standard of care. The FDA has granted SB-101 Rare Pediatric Disease Designation, placing us on a clear path to a Priority Review Voucher upon approval. Our pipeline extends to broader populations suffering from hepatic insufficiency, including both acute and chronic liver disease.